OTLK

NASDAQ open

Outlook Therapeutics

0.37 USD
▼-0.04-8.83%
盘后 0.43 0.00%
2026-11-20
市值
$94.94M
市盈率
—
EPS
-0.75
股息率
—
52 周区间
0.16 – 2.54
成交量
3.25M
Beta
0.72
目标价
4.82
52W 低 0.1652W 高 2.54
价格走势

公司简介

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, ...